|
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. |
| |
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi |
| |
|
Honoraria - Abbvie; Amgen; Celgene; Genentech/Roche; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Research Funding - Celgene (Inst); Janssen (Inst) |
| |
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Immuneel Therapeutics; Janssen Oncology; Merck; Pfizer; Takeda |
Research Funding - Bluebird Bio (Inst) |
| |
|
Honoraria - Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Takeda |
Consulting or Advisory Role - Celgene; Takeda |
Research Funding - Celgene (Inst); Janssen (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Takeda |
| |
Bhagirathbhai R. Dholaria |
Stock and Other Ownership Interests - Bluebird Bio; Iovance Biotherapeutics; Moderna Therapeutics; Syndax |
Honoraria - Adaptive Biotechnologies; Curio Science; MJH Healthcare Holdings, LLC; Wiley |
Consulting or Advisory Role - arivan research; Celgene; Jazz Pharmaceuticals |
Research Funding - Angiocrine Bioscience (Inst); Janssen Oncology (Inst); MEI Pharma (Inst); Pfizer (Inst); poseida therapeutics (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - MedCity News |
| |
|
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Seagen |
Research Funding - Partner therapeutics |
| |
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Sanofi; Seagen; Takeda |
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Sanofi; Seagen; Takeda |
Research Funding - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Sanofi; Seagen; Takeda |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline |
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Janssen; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Janssen |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; Sanofi; Takeda |
Research Funding - Janssen |
| |
|
Honoraria - ITeos Therapeutics; Janssen; Legend Biotech; Pfizer; Sanofi; Trillium Therapeutics |
Consulting or Advisory Role - Pfizer; Trillium Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst); Trillium Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Serametrix, Inc |